Skip to main content
Equibles

Casdin Capital, LLC

Position in NTLA — Intellia Therapeutics, Inc.

CIK 1534261 New York, NY
Back to NTLA Full portfolio

Position in NTLA

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$6,006,600
+$1,455,500 QoQ
Shares Held
355,000
0.0% QoQ
Ownership
0.253%
of shares outstanding
% of Portfolio
0.30%
of 13F equity value
Holder Rank
#52
of 330 holders
Holding Since
Sep 2022
13 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NTLA Over Time

Shares Held

Position Value (USD)

Derivatives in NTLA

reported options exposure · as of Mar 31, 2024
CallValue
$1,375,500
CallShares
50,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Casdin Capital, LLC holds $1,258,350,419 across 31 Biotechnology names. NTLA ranks #20 (0.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 2,577,333 $482,682,924
2 RLAY
Relay Therapeutics, Inc.
 16,035,240 $300,019,340
3 GPCR
Structure Therapeutics Inc.
 1,175,000 $63,062,250
4 DNLI
Denali Therapeutics Inc.
 2,045,000 $52,597,400
5 NGNE
Neurogene Inc.
 1,545,361 $48,601,603
6 BEAM
Beam Therapeutics Inc.
 1,350,000 $46,332,000
7 SRRK
Scholar Rock Holding Corp
 665,000 $36,575,000
8 MAZE
Maze Therapeutics, Inc.
 843,857 $25,180,692

All Filings in NTLA

Export CSV
14 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $6,006,600 355,000
2026-03-31 $4,551,100 355,000
2025-03-31 $14,220,000 2,000,000
2024-12-31 $23,320,000 2,000,000
2024-09-30 $41,100,000 2,000,000
2024-06-30 $44,760,000 2,000,000
2024-03-31 $1,375,500 50,000
2024-03-31 $51,581,250 1,875,000
2023-12-31 $44,210,500 1,450,000
2023-09-30 $37,250,731 1,178,075
2023-06-30 $51,994,500 1,275,000
2023-03-31 $47,519,250 1,275,000
2022-12-31 $10,292,550 295,000
2022-09-30 $16,508,200 295,000